Caligan Partners LP Has $15.72 Million Stake in Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB)

Caligan Partners LP boosted its stake in Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB - Free Report) by 105.3% during the third quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 1,195,253 shares of the company's stock after purchasing an additional 613,175 shares during the period. Y-mAbs Therapeutics comprises 5.0% of Caligan Partners LP's investment portfolio, making the stock its 8th largest position. Caligan Partners LP owned 2.67% of Y-mAbs Therapeutics worth $15,718,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other hedge funds and other institutional investors have also recently bought and sold shares of YMAB. Zurcher Kantonalbank Zurich Cantonalbank bought a new position in shares of Y-mAbs Therapeutics during the third quarter valued at about $44,000. China Universal Asset Management Co. Ltd. increased its holdings in Y-mAbs Therapeutics by 66.3% during the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 8,572 shares of the company's stock valued at $113,000 after purchasing an additional 3,416 shares during the period. Intech Investment Management LLC bought a new position in Y-mAbs Therapeutics during the 3rd quarter valued at approximately $133,000. SG Americas Securities LLC purchased a new stake in Y-mAbs Therapeutics in the 3rd quarter worth approximately $178,000. Finally, Principal Financial Group Inc. bought a new stake in shares of Y-mAbs Therapeutics in the 3rd quarter worth approximately $267,000. Institutional investors own 70.85% of the company's stock.

Insider Transactions at Y-mAbs Therapeutics

In related news, insider Thomas Gad sold 30,000 shares of the company's stock in a transaction that occurred on Monday, September 16th. The stock was sold at an average price of $12.97, for a total value of $389,100.00. Following the transaction, the insider now directly owns 67,681 shares of the company's stock, valued at approximately $877,822.57. This represents a 30.71 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. 22.50% of the stock is owned by insiders.

Y-mAbs Therapeutics Stock Up 0.3 %

Shares of NASDAQ YMAB traded up $0.04 on Friday, reaching $11.92. 189,369 shares of the company's stock traded hands, compared to its average volume of 287,886. The business's 50 day simple moving average is $13.46 and its two-hundred day simple moving average is $12.81. Y-mAbs Therapeutics, Inc. has a 12 month low of $6.00 and a 12 month high of $20.90. The company has a market cap of $533.88 million, a price-to-earnings ratio of -22.07 and a beta of 0.68.

Y-mAbs Therapeutics (NASDAQ:YMAB - Get Free Report) last posted its quarterly earnings results on Friday, November 8th. The company reported ($0.16) earnings per share for the quarter, missing the consensus estimate of ($0.14) by ($0.02). Y-mAbs Therapeutics had a negative return on equity of 24.61% and a negative net margin of 28.22%. The company had revenue of $18.46 million during the quarter, compared to analysts' expectations of $23.38 million. During the same quarter in the previous year, the company earned ($0.18) EPS. Analysts forecast that Y-mAbs Therapeutics, Inc. will post -0.64 earnings per share for the current fiscal year.

Analyst Ratings Changes

A number of brokerages recently commented on YMAB. Canaccord Genuity Group reaffirmed a "buy" rating and issued a $26.00 price target on shares of Y-mAbs Therapeutics in a research note on Tuesday, August 13th. Morgan Stanley dropped their target price on shares of Y-mAbs Therapeutics from $12.00 to $11.00 and set an "underweight" rating for the company in a research report on Tuesday, August 13th. Cantor Fitzgerald reiterated an "overweight" rating and set a $20.00 price target on shares of Y-mAbs Therapeutics in a research report on Monday, September 9th. Canaccord Genuity Group upgraded shares of Y-mAbs Therapeutics to a "strong-buy" rating in a report on Tuesday, August 13th. Finally, HC Wainwright reaffirmed a "buy" rating and set a $22.00 price objective on shares of Y-mAbs Therapeutics in a research report on Friday, November 15th. One investment analyst has rated the stock with a sell rating, seven have assigned a buy rating and one has issued a strong buy rating to the company. According to MarketBeat, Y-mAbs Therapeutics has a consensus rating of "Moderate Buy" and a consensus target price of $21.38.

Y-mAbs Therapeutics Profile

Y-mAbs Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the development and commercialization of antibody based therapeutic products for the treatment of cancer in the United States and internationally. It offers DANYELZA, a monoclonal antibody in combination with granulocyte-macrophage colony-stimulating factor for the treatment of pediatric patients with relapsed or refractory high-risk neuroblastoma in the bone or bone marrow.